Presentation is loading. Please wait.

Presentation is loading. Please wait.

Gene Colice, MD, Richard J

Published byEverett Craig Modified over 5 years ago

Similar presentations

Presentation on theme: "Gene Colice, MD, Richard J"— Presentation transcript:

1 Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone 
Gene Colice, MD, Richard J. Martin, MD, Elliot Israel, MD, Nicolas Roche, MD, PhD, Neil Barnes, MBBS, FRCP, Anne Burden, MSc, Peter Polos, MD, Paul Dorinsky, MD, Elizabeth V. Hillyer, DVM, Amanda J. Lee, PhD, Alison Chisholm, MSc, Julie von Ziegenweidt, Francesca Barion, PhD, David Price, FRCGP  Journal of Allergy and Clinical Immunology  Volume 132, Issue 1, Pages e10 (July 2013) DOI: /j.jaci Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 ICS dose for matched cohorts, as prescribed on the index date for the initiation population. All differences in dose between the extrafine HFA-beclomethasone and fluticasone cohorts were statistically significant (P < .001). FP, Fluticasone propionate; HFA-BDP, hydrofluoroalkane–beclomethasone dipropionate. Journal of Allergy and Clinical Immunology  , e10DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 Proportion of patients in the initiation population by treatment cohort who achieved the overall control (risk and impairment) measure during the outcome year categorized by consumed ICS dose (ie, prescribed ICS divided by 365; A) and by MPR for ICSs (B). Exacerbation rates by MPR (C) and the proportion of patients who achieved the risk-domain asthma control measure by MPR (D) are shown also. Patient count percentages might not equal 100% because of rounding. FP, Fluticasone propionate; HFA-BDP, hydrofluoroalkane–beclomethasone dipropionate. Journal of Allergy and Clinical Immunology  , e10DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 2 Proportion of patients in the initiation population by treatment cohort who achieved the overall control (risk and impairment) measure during the outcome year categorized by consumed ICS dose (ie, prescribed ICS divided by 365; A) and by MPR for ICSs (B). Exacerbation rates by MPR (C) and the proportion of patients who achieved the risk-domain asthma control measure by MPR (D) are shown also. Patient count percentages might not equal 100% because of rounding. FP, Fluticasone propionate; HFA-BDP, hydrofluoroalkane–beclomethasone dipropionate. Journal of Allergy and Clinical Immunology  , e10DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig E1 Identification of eligible patients from the database for the initiation (A) and step-up (B) populations. Patients in the 2 treatment cohorts (HFA-beclomethasone and fluticasone) of each study population were then matched on 5 demographic and baseline criteria that could be predictive of or influence asthma control. COPD, Chronic obstructive pulmonary disease; DPI, dry powder inhaler; FP, fluticasone propionate; HFA-BDP, hydrofluoroalkane–beclomethasone dipropionate. Journal of Allergy and Clinical Immunology  , e10DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig E1 Identification of eligible patients from the database for the initiation (A) and step-up (B) populations. Patients in the 2 treatment cohorts (HFA-beclomethasone and fluticasone) of each study population were then matched on 5 demographic and baseline criteria that could be predictive of or influence asthma control. COPD, Chronic obstructive pulmonary disease; DPI, dry powder inhaler; FP, fluticasone propionate; HFA-BDP, hydrofluoroalkane–beclomethasone dipropionate. Journal of Allergy and Clinical Immunology  , e10DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

7 Fig E2 ICS dose for matched cohorts as prescribed on the index date for the step-up population. All differences in dose between the extrafine HFA-beclomethasone and fluticasone cohorts were statistically significant (P < .001). FP, Fluticasone propionate; HFA-BDP, hydrofluoroalkane–beclomethasone dipropionate. Journal of Allergy and Clinical Immunology  , e10DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

8 Fig E3 Proportion of patients in the step-up population by treatment cohort who achieved risk-domain asthma control (A) and exacerbation rates (B) during the outcome year categorized by MPR for ICS. FP, Fluticasone propionate; HFA-BDP, hydrofluoroalkane–beclomethasone dipropionate. Journal of Allergy and Clinical Immunology  , e10DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Gene Colice, MD, Richard J"

Similar presentations

A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay Jing Lin, PhD, Francesca M. Bruni,

A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay Jing Lin, PhD, Francesca M. Bruni,
Early exposure to cow's milk protein is protective against IgE-mediated cow's milk protein allergy Yitzhak Katz, MD, Nelly Rajuan, MSc, Michael R. Goldberg,

Early exposure to cow's milk protein is protective against IgE-mediated cow's milk protein allergy Yitzhak Katz, MD, Nelly Rajuan, MSc, Michael R. Goldberg,
Endoplasmic reticulum stress influences bronchial asthma pathogenesis by modulating nuclear factor κB activation So Ri Kim, MD, PhD, Dong Im Kim, MS, Mi.

Endoplasmic reticulum stress influences bronchial asthma pathogenesis by modulating nuclear factor κB activation So Ri Kim, MD, PhD, Dong Im Kim, MS, Mi.
D-dimer: A biomarker for antihistamine-resistant chronic urticaria

D-dimer: A biomarker for antihistamine-resistant chronic urticaria
Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered- dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder.

Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered- dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder.
Comparative outcomes of leukotriene receptor antagonists and long-acting β-agonists as add-on therapy in asthmatic patients: A population-based study 

Comparative outcomes of leukotriene receptor antagonists and long-acting β-agonists as add-on therapy in asthmatic patients: A population-based study 
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery  Albertien A.C. Aukema,

Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery  Albertien A.C. Aukema,
Risk of an asthma exacerbation after bariatric surgery in adults

Risk of an asthma exacerbation after bariatric surgery in adults
Small-particle Inhaled Corticosteroid as First-line or Step-up Controller Therapy in Childhood Asthma  Willem M.C. van Aalderen, MD, PhD, Jonathan Grigg,

Small-particle Inhaled Corticosteroid as First-line or Step-up Controller Therapy in Childhood Asthma  Willem M.C. van Aalderen, MD, PhD, Jonathan Grigg,
Differential effects of maintenance long-acting β-agonist and inhaled corticosteroid on asthma control and asthma exacerbations  Peter G. Gibson, MBBS(Hons),

Differential effects of maintenance long-acting β-agonist and inhaled corticosteroid on asthma control and asthma exacerbations  Peter G. Gibson, MBBS(Hons),
The prevalence of severe refractory asthma

The prevalence of severe refractory asthma
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 
Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies  Stuart W Stoloff,

Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies  Stuart W Stoloff,
Severe winter asthma exacerbations can be prevented by omalizumab, but there is no carryover effect  Peter D. Sly, MD, DSc, Julie Varghese, BHMS, PGDCTM,

Severe winter asthma exacerbations can be prevented by omalizumab, but there is no carryover effect  Peter D. Sly, MD, DSc, Julie Varghese, BHMS, PGDCTM,
Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol  Ian D. Pavord, DM, FRCP, Peter K. Jeffery,

Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol  Ian D. Pavord, DM, FRCP, Peter K. Jeffery,

Similar presentations

Ads by Google